@ARTICLE{TreeBASE2Ref25488,
author = {Joao Paulo Siqueira and Deanna A. Sutton and Dania Garcia and Josepa Gene and Pamela Thomson and Nathan P Wiederhold and Josep Guarro},
title = {Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility},
year = {2016},
keywords = {},
doi = {},
url = {http://},
pmid = {},
journal = {Fungal Biology},
volume = {},
number = {},
pages = {},
abstract = {Aspergillus section Versicolores includes species of clinical relevance and many others that have been poorly studied but are occasionally found in clinical samples. The aim of this study was to investigate, using a multi-locus phylogenetic approach, the spectrum of species of the section Versicolores and to determine their in vitro antifungal susceptibility. The study was based on a set of 77 clinical isolates from different USA medical centers, which had been previously identified as belonging to this section. The genetic markers used were ITS, BenA, CaM and RPB2, and the drugs tested, following the CLSI guidelines, were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, terbinafine and flucytosine. The most frequent species were A. sydowii (26%), A. creber (22%) and A. amoenus (18.2%), followed by A. protuberus (13%), A. jensenii (10.4%), and A. tabacinus (5.2%); while A. cvjetkovicii, A. fructus, A. puulaauensis and A. versicolor were represented by only one isolate each (1.3%). This is the first time that A. jensenii and A. puulaauensis have been reported from clinical samples. Considering the high number of isolates identified as belonging to this fungal group in this study, its clinical relevance should not be overlooked. Aspergillus versicolor, traditionally considered one of the most common species in this section in a clinical setting, was only rarely recovered in our study. The in vitro antifungal results showed that echinocandins and terbinafine were the most potent drugs, the azoles showed variable results, amphotericin B was poorly active, and 5-fluorocytosine was the less active.}
}
Citation for Study 18777
Citation title:
"Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility".
Study name:
"Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility".
This study is part of submission 18777
(Status: Published).
Citation
Siqueira J.P., Sutton D., Garcia D., Gene J., Thomson P., Wiederhold N.P., & Guarro J. 2016. Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility. Fungal Biology, .
Authors
-
Siqueira J.P.
-
Sutton D.
-
Garcia D.
-
Gene J.
-
Thomson P.
-
Wiederhold N.P.
-
Guarro J.
Abstract
Aspergillus section Versicolores includes species of clinical relevance and many others that have been poorly studied but are occasionally found in clinical samples. The aim of this study was to investigate, using a multi-locus phylogenetic approach, the spectrum of species of the section Versicolores and to determine their in vitro antifungal susceptibility. The study was based on a set of 77 clinical isolates from different USA medical centers, which had been previously identified as belonging to this section. The genetic markers used were ITS, BenA, CaM and RPB2, and the drugs tested, following the CLSI guidelines, were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, terbinafine and flucytosine. The most frequent species were A. sydowii (26%), A. creber (22%) and A. amoenus (18.2%), followed by A. protuberus (13%), A. jensenii (10.4%), and A. tabacinus (5.2%); while A. cvjetkovicii, A. fructus, A. puulaauensis and A. versicolor were represented by only one isolate each (1.3%). This is the first time that A. jensenii and A. puulaauensis have been reported from clinical samples. Considering the high number of isolates identified as belonging to this fungal group in this study, its clinical relevance should not be overlooked. Aspergillus versicolor, traditionally considered one of the most common species in this section in a clinical setting, was only rarely recovered in our study. The in vitro antifungal results showed that echinocandins and terbinafine were the most potent drugs, the azoles showed variable results, amphotericin B was poorly active, and 5-fluorocytosine was the less active.
External links
About this resource
- Canonical resource URI:
http://purl.org/phylo/treebase/phylows/study/TB2:S18777
- Other versions:
Nexus
NeXML
- Show BibTeX reference
@ARTICLE{TreeBASE2Ref25488,
author = {Joao Paulo Siqueira and Deanna A. Sutton and Dania Garcia and Josepa Gene and Pamela Thomson and Nathan P Wiederhold and Josep Guarro},
title = {Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility},
year = {2016},
keywords = {},
doi = {},
url = {http://},
pmid = {},
journal = {Fungal Biology},
volume = {},
number = {},
pages = {},
abstract = {Aspergillus section Versicolores includes species of clinical relevance and many others that have been poorly studied but are occasionally found in clinical samples. The aim of this study was to investigate, using a multi-locus phylogenetic approach, the spectrum of species of the section Versicolores and to determine their in vitro antifungal susceptibility. The study was based on a set of 77 clinical isolates from different USA medical centers, which had been previously identified as belonging to this section. The genetic markers used were ITS, BenA, CaM and RPB2, and the drugs tested, following the CLSI guidelines, were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, terbinafine and flucytosine. The most frequent species were A. sydowii (26%), A. creber (22%) and A. amoenus (18.2%), followed by A. protuberus (13%), A. jensenii (10.4%), and A. tabacinus (5.2%); while A. cvjetkovicii, A. fructus, A. puulaauensis and A. versicolor were represented by only one isolate each (1.3%). This is the first time that A. jensenii and A. puulaauensis have been reported from clinical samples. Considering the high number of isolates identified as belonging to this fungal group in this study, its clinical relevance should not be overlooked. Aspergillus versicolor, traditionally considered one of the most common species in this section in a clinical setting, was only rarely recovered in our study. The in vitro antifungal results showed that echinocandins and terbinafine were the most potent drugs, the azoles showed variable results, amphotericin B was poorly active, and 5-fluorocytosine was the less active.}
}
- Show RIS reference
TY - JOUR
ID - 25488
AU - Siqueira,Joao Paulo
AU - Sutton,Deanna A.
AU - Garcia,Dania
AU - Gene,Josepa
AU - Thomson,Pamela
AU - Wiederhold,Nathan P
AU - Guarro,Josep
T1 - Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility
PY - 2016
KW -
UR - http://dx.doi.org/
N2 - Aspergillus section Versicolores includes species of clinical relevance and many others that have been poorly studied but are occasionally found in clinical samples. The aim of this study was to investigate, using a multi-locus phylogenetic approach, the spectrum of species of the section Versicolores and to determine their in vitro antifungal susceptibility. The study was based on a set of 77 clinical isolates from different USA medical centers, which had been previously identified as belonging to this section. The genetic markers used were ITS, BenA, CaM and RPB2, and the drugs tested, following the CLSI guidelines, were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, terbinafine and flucytosine. The most frequent species were A. sydowii (26%), A. creber (22%) and A. amoenus (18.2%), followed by A. protuberus (13%), A. jensenii (10.4%), and A. tabacinus (5.2%); while A. cvjetkovicii, A. fructus, A. puulaauensis and A. versicolor were represented by only one isolate each (1.3%). This is the first time that A. jensenii and A. puulaauensis have been reported from clinical samples. Considering the high number of isolates identified as belonging to this fungal group in this study, its clinical relevance should not be overlooked. Aspergillus versicolor, traditionally considered one of the most common species in this section in a clinical setting, was only rarely recovered in our study. The in vitro antifungal results showed that echinocandins and terbinafine were the most potent drugs, the azoles showed variable results, amphotericin B was poorly active, and 5-fluorocytosine was the less active.
L3 -
JF - Fungal Biology
VL -
IS -
ER -